Nordea Investment Management AB grew its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 26.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 259,372 shares of the company's stock after acquiring an additional 53,944 shares during the period. Nordea Investment Management AB owned 0.29% of Arcus Biosciences worth $4,892,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of RCUS. GAMMA Investing LLC grew its holdings in Arcus Biosciences by 51.6% during the first quarter. GAMMA Investing LLC now owns 2,427 shares of the company's stock valued at $46,000 after purchasing an additional 826 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Arcus Biosciences by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 12,940 shares of the company's stock worth $244,000 after acquiring an additional 1,090 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Arcus Biosciences by 5.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 32,356 shares of the company's stock valued at $583,000 after acquiring an additional 1,702 shares during the period. Exchange Traded Concepts LLC grew its position in shares of Arcus Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,816 shares of the company's stock valued at $130,000 after purchasing an additional 1,729 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in Arcus Biosciences during the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 92.89% of the company's stock.
Analysts Set New Price Targets
Several research analysts have commented on the company. Citigroup lifted their price target on Arcus Biosciences from $36.00 to $38.00 and gave the stock a "buy" rating in a research report on Monday, June 3rd. Truist Financial cut their target price on shares of Arcus Biosciences from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, June 24th. Barclays decreased their price objective on Arcus Biosciences from $35.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcus Biosciences in a research note on Friday, July 5th. Finally, Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Arcus Biosciences in a research note on Thursday, May 9th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $38.11.
Check Out Our Latest Analysis on RCUS
Arcus Biosciences Trading Down 1.0 %
Shares of RCUS traded down $0.14 during trading hours on Wednesday, hitting $13.94. 738,119 shares of the stock traded hands, compared to its average volume of 784,309. The business has a fifty day moving average of $15.83 and a 200-day moving average of $16.68. The firm has a market capitalization of $1.27 billion, a PE ratio of -4.48 and a beta of 0.90. Arcus Biosciences, Inc. has a 1-year low of $12.95 and a 1-year high of $25.47.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.92. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative return on equity of 40.98% and a negative net margin of 97.47%. The firm's quarterly revenue was up 480.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.09) EPS. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -2.61 earnings per share for the current fiscal year.
Arcus Biosciences Profile
(
Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
![Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=RCUS)
Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.